Top Companies Driving Biopharmaceutical Contract Manufacturing
Biopharma Outsourcing on the Rise!
The Biopharmaceutical Contract Manufacturing Market is projected to skyrocket from USD 11.23 Billion in 2025 to USD 26.93 Billion by 2035 📈 that’s a solid CAGR of 8.8%.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://www.futuremarketinsights.com/reports/sample/rep-gb-2982
💡 Why the surge?
- Rising complexity of biologics 🧬
- Limited in-house capabilities at pharma firms
- Strong demand for mammalian-based expression systems (72.5% share in 2025)
- Outsourcing for monoclonal antibodies, vaccines, & gene therapies
🌏 Hotspots: China, India, Japan = fastest-growing markets
🏭 Key moves:
- Thermo Fisher Scientific expands biologics facility in Hangzhou 🇨🇳
- Sartorius integrates single-use bioreactors for speed & scale
- FDA CMC 2025 guideline boosts faster approvals
📊 Future Outlook: Mammalian systems remain dominant; microbial-based platforms gain traction for cost-sensitive biologics.
